Cytokinetics (CYTK) EVP executes 3,500-share option exercise and sale

Rhea-AI Filing Summary

Cytokinetics EVP of Research & Development Fady Ibraham Malik exercised stock options and sold the resulting shares. He exercised 3,500 shares of common stock through a non-qualified stock option at $7.80 per share, then completed an open-market sale of 3,500 shares at $77.37 per share on the same date. Following these transactions, he directly held 153,902 shares of Cytokinetics common stock, indicating his overall share count remained broadly stable after the exercise-and-sell sequence.

Insights

Equity compensation and insider-trading analyst

Routine option exercise-and-sell by Cytokinetics EVP with minimal position change.

The filing shows EVP of Research & Development Fady Ibraham Malik exercising a non-qualified stock option for 3,500 shares at $7.80 and selling the same number of shares at $77.37. This is a classic exercise-and-sell pattern converting an option award into cash.

After the transactions, Malik directly held 153,902 shares of common stock, so the activity represents a small fraction of his visible equity stake. The derivative record indicates 51,386 stock options remained outstanding after this exercise, with an expiration date in 2028, suggesting he still has substantial option-based exposure.

Given the limited scale relative to his total holdings and the compensation-driven nature of option exercises, this appears to be a routine liquidity event rather than a major shift in insider sentiment. Future company filings may provide further detail on any additional exercises from this option grant or other awards.

Insider Trade Summary 10b5-1

Net Seller: 3,500 shares ($270,795)

Net Sell 3 txns

Insider Malik Fady Ibraham

Role EVP Research & Development

Sold 3,500 shs ($271K)

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy)	3,500	$0.00	--
Exercise	Common Stock	3,500	$7.80	$27K
Sale	Common Stock	3,500	$77.37	$271K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 51,386 shares (Direct, null); Common Stock — 157,402 shares (Direct, null)

Footnotes (1)

Key Figures

Shares sold: 3,500 shares Sale price: $77.37 per share Options exercised: 3,500 shares +4 more

7 metrics

Shares sold 3,500 shares Open-market sale of common stock

Sale price $77.37 per share Price for 3,500 common shares sold

Options exercised 3,500 shares Non-qualified stock option exercise

Option exercise price $7.80 per share Conversion or exercise price of option

Shares held after transactions 153,902 shares Direct common stock holdings post-sale

Options remaining 51,386 options Non-qualified stock options after exercise

Option expiration 2028-02-27 Expiration date of the option grant

Key Terms

open-market sale, Non-Qualified Stock Option (Right to Buy), derivative exercise/conversion, exercise or conversion of derivative security

4 terms

open-market sale financial

"transaction_action: "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Non-Qualified Stock Option (Right to Buy) financial

"security_title: "Non-Qualified Stock Option (Right to Buy)""

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion""

exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Research & Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/05/2026		M		3,500	A	$7.8	157,402	D
Common Stock	05/05/2026		S		3,500	D	$77.37	153,902	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$7.8	05/05/2026		M			3,500	03/27/2018	02/27/2028	Common Stock	3,500	$0	51,386	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Malik	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Cytokinetics (CYTK) EVP Fady Malik do in this Form 4 filing?

Fady Malik, EVP of Research & Development at Cytokinetics, exercised a stock option for 3,500 common shares at $7.80 and sold 3,500 shares at $77.37. This turned an existing option award into cash while leaving his overall share count essentially unchanged.

How many Cytokinetics (CYTK) shares did the EVP sell and at what price?

The executive sold 3,500 shares of Cytokinetics common stock in an open-market transaction at $77.37 per share. This sale followed the exercise of a non-qualified stock option covering the same 3,500 shares, effectively monetizing that portion of his equity award.

How many Cytokinetics (CYTK) shares does the EVP hold after these transactions?

After the reported transactions, Fady Malik directly held 153,902 shares of Cytokinetics common stock. This suggests the option exercise and matching sale did not materially alter his overall ownership stake, which remained sizable in absolute terms following the activity disclosed.

What stock option did the Cytokinetics (CYTK) EVP exercise in this Form 4?

He exercised a Non-Qualified Stock Option (Right to Buy) covering 3,500 shares of Cytokinetics common stock at a conversion or exercise price of $7.80. The option carried an expiration date in 2028, and 51,386 option shares remained outstanding afterward.

Is the Cytokinetics (CYTK) EVP’s Form 4 activity a buy or a sell signal?

The Form 4 shows a mixed pattern: an option exercise to acquire 3,500 shares at $7.80 and an open-market sale of 3,500 shares at $77.37. Because his total holdings stayed large and relatively stable, this appears as routine compensation-related liquidity rather than a major directional signal.